Ulrich Schuler

Ulrich Schuler

Auto-generated profile, based on publicly available information

Ulrich Schuler

Medical Clinic I, University Clinic of Technical University Dresden, Dresden, Germany

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2007 in Oncology Research and Treatment
Verified
Journal Article
Closed access
PDF file
USUlrich Schuler
Ulrich Schuler
SBSusanne Bammer
Susanne Bammer
WAWalter E. Aulitzky
Walter E. Aulitzky
CBClaudia Binder
Claudia Binder
ABAngelika Böhme
Angelika Böhme
GEGerhard Ehninger
Gerhard Ehninger
Safety, tolerability and efficacy of itraconazole and amphotericin B (AMB) were compared for empirical antifungal treatment of febrile neutropenic cancer patients. Patients and Methods: In an open, randomised study, 162 patients with at least 72 h of antimicrobial treatment received either intravenous followed by oral itraconazole suspension or intravenous AMB for a maximum of 28 days. Permanent discontinuation of study medication due to any adverse event was the primary safety parameter. Efficacy parameters included response and success rate for both treatment groups. Results: Significantly fewer itraconazole patients discontinued treatment due to any adverse event (22.2 vs. 56.8% AMB; p < 0.0001). The main reason for discontinuation was a rise in serum creatinine (1.2% itraconazole vs. 23.5% AMB). Renal toxicity was significantly higher and more drug-related adverse events occurred in the AMB group. Intention-to-treat (ITT) analysis showed favourable efficacy for itraconazole: response and success rate were both significantly higher than for AMB (61.7 vs. 42% and 70.4 vs. 49.3%, both p < 0.0001). Treatment failure was markedly reduced in itraconazole patients (25.9 vs. 43.2%), largely due to the better tolerability. Conclusions: Itraconazole was tolerated significantly better than conventional AMB and also showed advantages regarding efficacy. This study confirms the role of itraconazole as a useful and safe agent in empirical antifungal therapy of febrile neutropenic cancer patients.

15 February 1997 in Cytometry
Verified
Journal Article
Open access
PDF file
RNRalf Nowak
Ralf Nowak
UOUta Oelschlaegel
Uta Oelschlaegel
USUlrich Schuler
Ulrich Schuler
HZHeidrun Zengler
Heidrun Zengler
RHRita Hofmann
Rita Hofmann
MAMichael Andreeff
Michael Andreeff
By simultaneous DNA staining and immunophenotyping, the aneuploid blasts of acute lymphoblastic leukemia (ALL) can be quantitated by flow cytometry. The present study evaluates the application of this method for the detection of minimal residual disease (MRD). For this purpose leukemia cells with known aneuploidy were serially diluted with diploid bone marrow cells obtained after chemotherapy. These mixed samples were immunophenotyped using antibodies CD34, CD10, or CD19 and processed for DNA staining with propidium iodide. Fifty thousand cells were measured for each experiment and the results were compared with the analysis of control sample without added aneuploid cells. Aneuploid cells diluted to 1% were not detectable in 6/15 cases when DNA content analysis was used alone, and in dilutions of < 1%, these cells were not detectable. When DNA content and immunophenotype were simultaneously measured, aneuploidy was detectable in 15/15 cases at 1.00%, 6/6 at 0.50%, 16/16 at 0.10%, and 16/17 at 0.05%. Therefore this method may be useful for the detection of minimal residual disease in cases of aneuploid lymphoblastic leukemia. Cytometry 30:47–53, 1997.

22 March 2010 in Mycoses
Verified
Journal Article
Closed access
PDF file
TIThomas Illmer
Thomas Illmer
JBJana Babatz
Jana Babatz
SPStefan Pursche
Stefan Pursche
FSFriedrich Stölzel
Friedrich Stölzel
USUlrich Schuler
Ulrich Schuler
GEGerhard Ehninger
Gerhard Ehninger